ACA
FDMT icon

Atlas Capital Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Atlas Capital Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-675
Closed -$5.43K – 922
2022
Q3 		$5.43K Buy
+675
New +$6.11K ﹤0.01% 768
2022
Q2 		– Sell
-675
Closed -$10.2K – 987
2022
Q1 		$10.2K Buy
+675
New +$10.6K ﹤0.01% 703

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Atlas Capital Advisors's FDMT Position: Q4 2022 in Review

Atlas Capital Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 675 shares — an estimated $5.43K sold.

Atlas Capital Advisors first reported a position in FDMT in Q1 2022 and held it in 2 quarters. The position peaked at $10.2K in Q1 2022. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

  • Atlas Capital Advisors reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 675 4D Molecular Therapeutics shares in Q4 2022, an estimated $5.43K.
  • Atlas Capital Advisors first reported a position in 4D Molecular Therapeutics in Q1 2022 and held it in 2 quarters.
  • Atlas Capital Advisors's 4D Molecular Therapeutics position peaked at $10.2K in Q1 2022.
  • 96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.